TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22292502

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Waist/height ratio (WHtR)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Body fat percentage (BFP)
Number of subjects: 305
Study: 22292853

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone (Len + Dex)
Number of subjects: 63
Study: 22293175

Group type: EXPERIMENTAL
Intervention: ET-743
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: PPARγ agonists
Number of subjects: 1
Study: 22293660

Group type: EXPERIMENTAL
Intervention: Selumetinib (AZD6244) 75 mg twice daily
Number of subjects: 1
Study: 22294344

Group type: EXPERIMENTAL
Intervention: Anakinra 1-5 mg/kg/day for at least 36 months
Number of subjects: 26
Study: 22296955

Group type: EXPERIMENTAL
Intervention: AERAS-402
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCG
Number of subjects: 0
Study: 22296967

Group type: EXPERIMENTAL
Intervention: Parental sexual abuse
Number of subjects: 106
Study: 22297835

Group type: EXPERIMENTAL
Intervention: Surgical site infection (SSI)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Superficial infections
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Deep infections
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Infection locations
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Wound contamination classification and duration of operation
Number of subjects: 1008
Study: 22298167

Group type: EXPERIMENTAL
Intervention: Intravenous dobutamine infused to achieve 80% of the maximum heart rate response for age
Number of subjects: 167
Study: 22298637

Group type: EXPERIMENTAL
Intervention: Positive urine dipstick test (UDT) combined with estimated glomerular filtration rate (eGFR)
Number of subjects: 2465

Group type: COMPARATOR
Intervention: Negative urine dipstick test (UDT)
Number of subjects: 2465
Study: 22298797

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 30
Study: 22298944

Group type: EXPERIMENTAL
Intervention: RebiSmart™ electronic auto-injector for subcutaneous IFN β-1a
Number of subjects: 63
Study: 22298950

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (1 mg/5 mL), 0.02-0.1 mg/kg three times a day; n = 20
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo; n = 18
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 22300423

Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg twice daily)
Number of subjects: 196
Study: 22300696

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic medication
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: Risk stratification model based on echocardiographic values
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: Criteria for SCD risk
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: Overall incidence of SCD
Number of subjects: 1803
Study: 22300740

Group type: EXPERIMENTAL
Intervention: Computerized algorithm incorporating cinacalcet and active vitamin D
Number of subjects: 92
Study: 22302299

Group type: EXPERIMENTAL
Intervention: Phrenic nerve stimulation (PNS) using Eupnea System device at a maximum of 10 mA
Number of subjects: 19
Study: 22302349

Group type: EXPERIMENTAL
Intervention: Erlotinib 100 mg daily, gemcitabine 1,000 mg/m2, cisplatin 25 mg/m2 administered on days 1 and 8 every 3 weeks.
Number of subjects: 22
Study: 22302620

Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lifestyle Change for Diabetes Prevention
Number of subjects: 72
Study: 22302662

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels >0.21 ng/mL without antibiotic treatment
Number of subjects: 1641

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels <0.05 ng/mL without antibiotic treatment
Number of subjects: 1641

Group type: EXPERIMENTAL
Intervention: Combination of physician estimates and PCT values
Number of subjects: 1641

Group type: EXPERIMENTAL
Intervention: PCT model alone
Number of subjects: 1641
Study: 22304793

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (dosage not specified)
Number of subjects: 40600

Group type: COMPARATOR
Intervention: Rosuvastatin 40 mg
Number of subjects: 40600

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg
Number of subjects: 40600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40600
Study: 22305169

Group type: EXPERIMENTAL
Intervention: Flax drink (3/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Flax bread (3/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control diet (low-fiber)
Number of subjects: 17
Study: 22305329

Group type: EXPERIMENTAL
Intervention: Canadian Triage and Acuity Scale
Number of subjects: 1464
Study: 22305344

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) with implants; no specific dosage or duration mentioned.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) with IPG replacement; no specific dosage or duration mentioned.
Number of subjects: 6
Study: 22306782

Group type: EXPERIMENTAL
Intervention: valsartan 80-160 mg
Number of subjects: 38
Study: 22306849

Group type: EXPERIMENTAL
Intervention: Semiautomated tool for assessing retinal vessel caliber (AVIx calculator)
Number of subjects: 210
Study: 22307813

Group type: EXPERIMENTAL
Intervention: Definite varus thrust
Number of subjects: 82

Group type: COMPARATOR
Intervention: No definite varus thrust
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Varus alignment
Number of subjects: 82

Group type: COMPARATOR
Intervention: No varus alignment
Number of subjects: 82
Study: 22308041

Group type: EXPERIMENTAL
Intervention: hyperinsulinemic-euglycemic plus intralipid and heparin
Number of subjects: 18

Group type: COMPARATOR
Intervention: saline infusion (SAL)
Number of subjects: 18
Study: 22308240

Group type: EXPERIMENTAL
Intervention: Structured reading algorithm (SEA-AF)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Standard telemetry without structured reading
Number of subjects: 346

Group type: COMPARATOR
Intervention: Daily electrocardiographic assessments
Number of subjects: 346
Study: 22308288

Group type: EXPERIMENTAL
Intervention: CD20-specific CAR T-cell infusion after cyclophosphamide lymphodepletion
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: CD20-specific CAR T-cell infusion
Number of subjects: 4
Study: 22308295

Group type: EXPERIMENTAL
Intervention: plerixafor 0.24 mg/kg/d in combination with mitoxantrone, etoposide, and cytarabine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: plerixafor
Number of subjects: 52
Study: 22308299

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 358
Study: 22311420

Group type: EXPERIMENTAL
Intervention: 7 days of aerobic exercise training (7D-EX)
Number of subjects: 13
Study: 22312169

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment
Number of subjects: 319
Study: 22314007

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 1333
Study: 22315486

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg for 28 days (one cycle) for a total of six cycles or until disease progression
Number of subjects: 36
Study: 22316363

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 255
Study: 22316567

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1124

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 1124

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 1124

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 1124

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 1124

Group type: EXPERIMENTAL
Intervention: All medication groups
Number of subjects: 1124
Study: 22316571

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Number of subjects: 29
Study: 22317913

Group type: EXPERIMENTAL
Intervention: Cionni-modified capsule tension ring (CTR) implantation with in-the-bag single-piece AcrySof intraocular lens (IOL) implantation
Number of subjects: 41
Study: 22318219

Group type: EXPERIMENTAL
Intervention: PI-including cART regimens
Number of subjects: 81
Study: 22318666

Group type: EXPERIMENTAL
Intervention: High-value conditional cash transfer ($20 per testing round)
Number of subjects: 2399

Group type: COMPARATOR
Intervention: Control group (n=1124)
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Low-value conditional cash transfer ($10 per testing round)
Number of subjects: 2399
Study: 22318751

Group type: EXPERIMENTAL
Intervention: BMI 25 to 29.9
Number of subjects: 31231

Group type: EXPERIMENTAL
Intervention: BMI 30 or more
Number of subjects: 31231

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 31231

Group type: EXPERIMENTAL
Intervention: Overweight and obese postmenopausal participants
Number of subjects: 31231
Study: 22318758

Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD) 400 kcal/d for 7 days
Number of subjects: 14
Study: 22319063

Group type: EXPERIMENTAL
Intervention: Acute incomplete stent apposition (ISA) segments
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Acute incomplete stent apposition (ISA) size (volume or maximum distance per strut)
Number of subjects: 43
Study: 22320292

Group type: EXPERIMENTAL
Intervention: Modified International Caries Detection and Assessment System II
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Standardization sessions
Number of subjects: 60
Study: 22321019

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Nicotine spray
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 935

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 935
Study: 22322081

Group type: EXPERIMENTAL
Intervention: Intracoronary acetylcholine (ACH) testing
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group (patients with normal coronary arteries or minimal irregularities)
Number of subjects: 304
Study: 22322531

Group type: EXPERIMENTAL
Intervention: Preoperative BNP (brain natriuretic peptide) levels categorized into quintiles
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Preoperative BNP
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Clinical parameters alone
Number of subjects: 1139
Study: 22323303

Group type: EXPERIMENTAL
Intervention: Positive airway pressure therapy
Number of subjects: 52
Study: 22323416

Group type: EXPERIMENTAL
Intervention: Oral antidiabetes drugs (OADs)
Number of subjects: 12527

Group type: COMPARATOR
Intervention: No oral antidiabetes drugs (OADs)
Number of subjects: 12527

Group type: EXPERIMENTAL
Intervention: Overall population (both OAD and non-OAD users)
Number of subjects: 12527
Study: 22323451

Group type: EXPERIMENTAL
Intervention: Mutation in the CCAAT box of the TERC gene promoter
Number of subjects: 0
Study: 22323509

Group type: EXPERIMENTAL
Intervention: PRE-DELIRIC model
Number of subjects: 3056

Group type: COMPARATOR
Intervention: Nurses' and physicians' predictions
Number of subjects: 3056
Study: 22325048

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg/week
Number of subjects: 108
Study: 22325068

Group type: EXPERIMENTAL
Intervention: High cocoa consumers
Number of subjects: 351

Group type: COMPARATOR
Intervention: Non-cocoa consumers
Number of subjects: 351
Study: 22325357

Group type: EXPERIMENTAL
Intervention: Afatinib (BIBW 2992)
Number of subjects: 5
Study: 22325452

Group type: EXPERIMENTAL
Intervention: dHER2 combined with lapatinib (1250 mg/day)
Number of subjects: 12
Study: 22326470

Group type: EXPERIMENTAL
Intervention: TMC435 monotherapy (200mg once daily for 7 days)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: TMC435 monotherapy (200mg once daily for 7 days) followed by PegIFN/RBV
Number of subjects: 37
Study: 22326922

Group type: EXPERIMENTAL
Intervention: GVAX combined with 3·0 mg/kg ipilimumab
Number of subjects: 28
Study: 22326924

Group type: EXPERIMENTAL
Intervention: Ipilimumab (1, 3, 5, and 10 mg/kg) in combination with PSA-Tricom vaccine (2×10^8 plaque-forming units on day 1, followed by 1×10^9 plaque-forming units monthly)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ipilimumab and PSA-Tricom vaccine
Number of subjects: 30
Study: 22326925

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to chemotherapy
Number of subjects: 70
Study: 22327493

Group type: EXPERIMENTAL
Intervention: HibMenCY
Number of subjects: 8500

Group type: COMPARATOR
Intervention: Hib (control)
Number of subjects: 8500
Study: 22327873

Group type: EXPERIMENTAL
Intervention: Intravenous vancomycin
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Antecedent antihistamine use
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Age > 2 years
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Previous RMS
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Vancomycin dose ≥ 10 mg/kg
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Vancomycin concentration ≥ 5 mg/mL
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: African American race
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism in the diamine oxidase gene
Number of subjects: 546
Study: 22328334

Group type: EXPERIMENTAL
Intervention: Integrated care for smoking cessation
Number of subjects: 863

Group type: COMPARATOR
Intervention: Usual care for smoking cessation
Number of subjects: 863
Study: 22328495

Group type: EXPERIMENTAL
Intervention: Continuous integrated distal capnography (dCap)
Number of subjects: 16
Study: 22329763

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills (OCPs) - monophasic OCP (20 μg ethinyl estradiol plus 75 μg gestodene), 21/28 days per cycle, during 6 months
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills (OCPs) with spironolactone 100 mg for 32 patients with severe hirsutism
Number of subjects: 49
Study: 22330017

Group type: EXPERIMENTAL
Intervention: PRO (40 g of intrinsically [1-C]phenylalanine-labeled casein protein)
Number of subjects: 16

Group type: COMPARATOR
Intervention: PLA (placebo, no protein)
Number of subjects: 16
Study: 22331118

Group type: EXPERIMENTAL
Intervention: Deep anterior lamellar keratoplasty (DALK) using the big-bubble technique
Number of subjects: 55
Study: 22331380

Group type: EXPERIMENTAL
Intervention: Isocaloric fructose intake
Number of subjects: 376

Group type: COMPARATOR
Intervention: Hypercaloric fructose intake
Number of subjects: 376
Study: 22331386

Group type: EXPERIMENTAL
Intervention: Specific resistance training for shoulder, neck and arm muscles three times a week (n=282)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Control group advised to continue normal physical activity (n=255)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Specific resistance training (n=54 with pain >30 mm VAS at baseline)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Control group (n=54 with pain >30 mm VAS at baseline)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Specific resistance training (n=113 with work disability >30 at baseline)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Control group (n=113 with work disability >30 at baseline)
Number of subjects: 537
Study: 22333218

Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg twice daily for the first month, then up-titrated to 125 mg twice daily.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bosentan treatment
Number of subjects: 12
Study: 22334638

Group type: EXPERIMENTAL
Intervention: Cerebral and abdominal MRI
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cerebral MRI
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cerebral and/or abdominal MRI
Number of subjects: 58
Study: 22335424

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (1.8 mg/m2) plus rituximab (375 mg/m2)
Number of subjects: 10
Study: 22336226

Group type: EXPERIMENTAL
Intervention: Thrombolysis in patients with ischemic stroke
Number of subjects: 0

Group type: COMPARATOR
Intervention: No thrombolysis in patients with ischemic stroke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with transient ischemic attack
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with ischemic stroke
Number of subjects: 0
Study: 22337718

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m(2)) in combination with CHOP-14
Number of subjects: 20
Study: 22339430

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (RLAI)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Oral olanzapine
Number of subjects: 96
Study: 22339949

Group type: EXPERIMENTAL
Intervention: BDNF Met allele carriers (n = 20)
Number of subjects: 128

Group type: COMPARATOR
Intervention: BDNF Val homozygotes (n = 34)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: BDNF genotype (Val(66)Met)
Number of subjects: 128
Study: 22340331

Group type: EXPERIMENTAL
Intervention: Pressure-driven lidocaine spray (2% lidocaine) with 10 L/min oxygen flow
Number of subjects: 30
Study: 22340437

Group type: EXPERIMENTAL
Intervention: Endovascular thrombolysis (local application of rt-plasminogen activator or urokinase, mechanical thrombosuction, or a combination of both) with heparin before and after the procedure.
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard therapy (therapeutic doses of heparin).
Number of subjects: 164
Study: 22341132

Group type: EXPERIMENTAL
Intervention: EyeSense biosensor
Number of subjects: 28
Study: 22342057

Group type: EXPERIMENTAL
Intervention: Intrasphincteric autologous myoblast injections followed by electrical stimulation (ES)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Preoperative electrical stimulation (ES) cycle
Number of subjects: 38
Study: 22342434

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Fosphenytoin (fos-PHT)
Number of subjects: 52
Study: 22342553

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22343511

Group type: EXPERIMENTAL
Intervention: Telbivudine
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 88
Study: 22343727

Group type: EXPERIMENTAL
Intervention: Rituximab-ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Rituximab-ABVD
Number of subjects: 49
Study: 22344775

Group type: EXPERIMENTAL
Intervention: Invasive group (patients with a positive test for myocardial ischaemia)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (patients with a negative test for myocardial ischaemia)
Number of subjects: 0
Study: 22344873

Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard endoscopy
Number of subjects: 72
Study: 22344964

Group type: EXPERIMENTAL
Intervention: Anti-infliximab (IFX) treatment
Number of subjects: 316
Study: 22345427

Group type: EXPERIMENTAL
Intervention: Ultra-endurance running exercise
Number of subjects: 11
Study: 22347360

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 15
Study: 22347526

Group type: EXPERIMENTAL
Intervention: Intratumoral placement of alloreactive cytotoxic T lymphocytes (alloCTL) with 30,000 IU of human recombinant Interleukin-2 in the cellular infusates.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alloreactive cytotoxic T lymphocytes (alloCTL)
Number of subjects: 0
Study: 22348003

Group type: EXPERIMENTAL
Intervention: Efalizumab (anti-CD11a)
Number of subjects: 0
Study: 22351714

Group type: COMPARATOR
Intervention: Free fructose in isocaloric trials
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: High doses of fructose in hypercaloric trials (+104 to 250 g/d, +18% to 97% of total daily energy intake)
Number of subjects: 756
Study: 22352764

Group type: EXPERIMENTAL
Intervention: NP101 transdermal sumatriptan patch
Number of subjects: 183
Study: 22353806

Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin (LD) 40 mg m(-2) plus cisplatin 60 mg m(-2) every 21 days
Number of subjects: 38
Study: 22354139

Group type: EXPERIMENTAL
Intervention: Falls in the earlier 6 months
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Basic Activities of Daily Living (BADL)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Earlier fall
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Dependence in BADL
Number of subjects: 626
Study: 22354206

Group type: EXPERIMENTAL
Intervention: DVD-R regimen (pegylated liposomal doxorubicin 4.0 mg/m(2), bortezomib 1.0 mg/m(2), dexamethasone 40 mg, lenalidomide 10 mg daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: DVD-R regimen
Number of subjects: 40
Study: 22356324

Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 132
Study: 22357361

Group type: EXPERIMENTAL
Intervention: Congestive heart failure patients receiving both beta-blockers and antagonists of the renin-angiotensin-aldosterone system (n=511)
Number of subjects: 3059

Group type: EXPERIMENTAL
Intervention: Congestive heart failure patients receiving neither renin-angiotensin-aldosterone system blockers nor beta-blockers (n=498)
Number of subjects: 3059

Group type: EXPERIMENTAL
Intervention: Congestive heart failure patients receiving only one of the recommended classes of medications
Number of subjects: 3059

Group type: COMPARATOR
Intervention: Patients without congestive heart failure
Number of subjects: 3059

Group type: EXPERIMENTAL
Intervention: Overall in-hospital mortality rate
Number of subjects: 3059

Group type: EXPERIMENTAL
Intervention: Overall 1-year mortality rate
Number of subjects: 3059

Group type: EXPERIMENTAL
Intervention: Presence of congestive heart failure
Number of subjects: 3059
Study: 22357572

Group type: EXPERIMENTAL
Intervention: Active-minocycline plus active-aspirin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Active-minocycline plus placebo-aspirin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Placebo-minocycline plus active-aspirin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo-minocycline plus placebo-aspirin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Minocycline and aspirin
Number of subjects: 120
Study: 22359536

Group type: EXPERIMENTAL
Intervention: Clinically diagnosed HD
Number of subjects: 2318

Group type: EXPERIMENTAL
Intervention: Clinically unaffected individuals with expanded alleles
Number of subjects: 2318

Group type: COMPARATOR
Intervention: Individuals without expanded alleles
Number of subjects: 2318
Study: 22360576

Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide
Number of subjects: 0
Study: 22360915

Group type: EXPERIMENTAL
Intervention: Concurrent prophylactic placement of inferior vena cava filter (CPIVCF)
Number of subjects: 322
Study: 22360944

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention and stenting with different drug-eluting coatings and platforms
Number of subjects: 0